紅斑性狼瘡相關新治療方法

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

Lupus erythematosus (LE), a family of chronic autoimmune diseases, ranges from skin disease to life-threatening systemic disease. Multiple therapy options are necessary, even for patients with similar symptoms-and there is great need for agents that can control the complications of systemic disease. LE therapy development is increasing, and many companies are investigating LE as an expansion indication.

Get the Answers You Need to Shape Your Strategy

The small lupus erythematosus (LE) patient population poses challenges to companies that are developing agents for this indication: enrollment for clinical trials can be diffi cult, and the sales potential of these agents is limited. What are companies doing to surmount these challenges? Although effective, few existing agents for cutaneous LE are considered safe enough for long-term use. An effective agent that is safe for prolonged treatment will have a signifi cant competitive advantage. Which agent now in development has the best chance to satisfy this need? Is any agent currently in development likely to displace current fi rst-line therapies? Because of the heterogeneous nature of systemic LE, the market can support many agents. But owing to the number of effective generics available, emerging agents must prove their greater effi cacy and safety to ensure adoption. What are the advantages and disadvantages of the emerging therapies' modes of action? How soon are new therapies likely to reach the market? What are their prospects for success in competition with generics and established therapies?

Scope

Etiology, pathophysiology, and prevalence: relationship of cutaneous lupus erythematosus (CLE) to systemic lupus erythematosus (SLE); prevalence of systemic lupus erythematosus in the three major-market regions by gender.

• Current therapies: overview of leading therapies for CLE and for SLE.
• Indications covered: CLE (discoid LE), acute CLE, subacute CLE, and SLE.
• Emerging therapies: overview of agents for development for CLE and SLE; late-stage agents are discussed in detail.
• Market outlook: challenges that emerging agents will face and their prospects for success.

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Cutaneous Lupus Erythematosus
• Disease Description and Etiology
• Prevalence
• Connection Between Cutaneous LE and Systemic LE
• Overview of Current Drug Therapies
• Corticosteroids
• Antimalarials
• Calcineurin Inhibitors
• Anti-Leprosy Agents
• Retinoids
• Systemic Lupus Erythematosus
• Disease Symptoms and Etiology
• Prevalence
• Overview of Current Drug Therapies
• Nonsteroidal Anti-Inflammatory Agents
• Corticosteroids
• Immunosuppressive/Immunomodulatory Agents
• Emerging Therapies for the Treatment of Cutaneous Lupus Erythematosus
• Genentech' s Efalizumab
• Astion Pharma' s ASF-1096
• Emerging Therapies for the Treatment of Systemic Lupus Erythematosus
• Immunomodulators
• Aspreva/Roche' s Mycophenolate Mofetil
• Wyeth' s Sirolimus
• Astellas' s Tacrolimus
• Biological Agents
• Genentech/Biogen Idec' s Rituximab
• UCB/Immunomedics' Epratuzumab
• Human Genome Science/GlaxoSmithKline' s Belimumab
• Bristol-Myers Squibb' s Abatacept
• Teva' s Edratide
• Other Approaches
• Genelabs Technologies' Prasterone
• La Jolla Pharmaceutical' s Abetimus Sodium
• Outlook

Tables

• 1. Current Therapies for the Treatment of Cutaneous Lupus Erythematosus
• 2. American College of Rheumatology Criteria for Classification of Systemic Lupus Erythematosus
• 3. Prevalent Cases of Systemic Lupus Erythematosus in the Three Major-Market Regions by Gender, 2005
• 4. Current Therapies for the Treatment of Systemic Lupus Erythematosus
• 5. Emerging Therapies for the Treatment of Cutaneous Lupus Erythematosus
• 6. Emerging Therapies for the Treatment of Systemic Lupus Erythematosus

Figures

• 1. Onset and Complications of Systemic Lupus Erythematosus
• 2. Immunopathological Targets of Emerging Biological Therapies for Systemic Lupus Erythematosus
• 3. Emerging Agents for SLE Approved or In Development for Other Indications

相關商品

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!